Diabetes
Additional phase I/II results show continued safety of NBI-6024 in adolescents
Published in Vaccine Weekly, July 17th, 2002
Neurocrine Biosciences, Inc., (NBIX) announced that all doses of NBI-6024 were well tolerated when administered subcutaneously in adolescent patients with type I diabetes, at the 62nd annual meeting of the American Diabetes Association (ADA) in San Francisco. NBI-6024, which Neurocrine is developing in collaboration with Taisho Pharmaceutical Co., Ltd., is a therapeutic vaccine developed using Neurocrine's Altered Peptide Ligand (APL) technology. The authors concluded that these safety findings support the expanded investigation of NBI-6024.
This phase I/II trial was conducted in 35 adolescent patients ages 12-17 years with insulin-dependent type I diabetes to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2002-07-17)
More Articles from Vaccine Weekly
- Vaccination
Influenza vaccination reduces risk of adverse cardiac events during flu season - Vaccine Development
Conjugated CD20 vaccine elicits specific, polyclonal immune response in mice - Hepatitis B Vaccine
Waiting to vaccinate against hepatitis B may be best policy for preterm infants - Vaccine Development
Novel Leishmania donovani protein potential vaccine antigen - Vaccine Development
Proteomic methods promising for antigen identification - Vaccine Development
Therapeutic HPV vaccine shows promise - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
